<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667420</url>
  </required_header>
  <id_info>
    <org_study_id>07326</org_study_id>
    <nct_id>NCT00667420</nct_id>
  </id_info>
  <brief_title>Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma</brief_title>
  <acronym>EOXP</acronym>
  <official_title>A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to determine the safety of using perioperative panitumumab with EOX
      (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus
      and stomach.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to slow accrual
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>after 3 cycles of pre-operative chemotherapy (approx 21 days per cycle)</time_frame>
    <description>Safety and tolerability were measured by assessing the number of participants able to complete 3 cycles of pre-operative chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>time of surgery = after 3 cycles (approx 63 days) of pre-operative EOX-P chemotherapy</time_frame>
    <description>percentage of participants who have microscopically negative margins (no tumor at/near the edge of what is resected) at the time of surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>up to 72 months</time_frame>
    <description>measured from the first day of treatment to the day when conclusive evidence of new disease is found</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>at surgical resection, after 3 cycles pre-operative chemotherapy (approx 63 days)</time_frame>
    <description>For patients who undergo complete resection, those who have no evidence of residual viable tumor in the surgical specimen will be declared to have achieved a complete pathologic response (pCR), and the overall percentage of patients with pCR will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>duration from enrollment to death (up to 6 years)</time_frame>
    <description>Overall survival (OS) is the duration from start of treatment to time of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Esophageal Adenocarcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>EOXP chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab, epirubicin, oxaliplatin, xeloda</intervention_name>
    <description>pilot study</description>
    <arm_group_label>EOXP chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed diagnosis of
             adenocarcinoma of the stomach, gastroesophageal junction, or lower third of the
             esophagus, AJCC stage II-IIIB (gastric) or IIA-IVA (esophageal). M1a disease will be
             included, but not T4 lesions.

          -  No prior radiation or chemotherapy including anti-EGFR or vascular endothelial growth
             factor (VEGF) antibody or tyrosine kinase inhibitor treatments.

          -  All patients must have staging endoscopic ultrasound (EUS) prior to enrollment.

          -  Men or Women &gt;18 years of Age

          -  ECOG performance status &lt;2 (Karnofsky &gt;60%, see Appendix A).

          -  Cardiac ejection fraction &gt;45% by echocardiogram or MUGA scan.

          -  Must be able to either swallow pills or have gastrostomy tube in place for
             administration of enteral medications.

          -  Patients must have normal organ, metabolic and marrow function as defined below:

               -  Hematologic function, as follows:

                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

                    -  Platelet count ≥ 100 x 109/L

                    -  Hemoglobin ≥ 9.0 g/dL

               -  Renal function, as follows:

                    -  Creatinine &lt; or = 1.5 mg/dL x ULN

        Hepatic function, as follows:

          -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)&lt; or = 3 x ULN

          -  Total bilirubin &lt; 1.5 x ULN

        Metabolic function, as follows:

          -  Magnesium ≥ lower limit of normal

          -  Calcium &lt; or = lower limit of normal -Human IgG is known to cross the placental
             barrier; therefore, Panitumumab may be transmitted from the mother to the developing
             fetus. In women of childbearing potential, appropriate contraceptive measures must be
             used during treatment with panitumumab and for 6 months following the last dose of
             panitumumab. If panitumumab is used during pregnancy or if the patient becomes
             pregnant while receiving this drug, she should be apprised of the potential risk for
             loss of the pregnancy or potential hazard to the fetus.

        3.1.10 Ability to understand and the willingness to sign and date a written IEC/IRB
        approved informed consent form.

        Exclusion Criteria:

          -  Evidence of distant metastatic disease.

          -  T4 tumor on initial staging studies.

          -  History of another primary cancer, except:

          -  Curatively treated in situ cervical cancer

          -  Curatively resected non-melanoma skin cancer

          -  Other primary solid tumor curatively treated with no known active disease present and
             no treatment administered for ³ 5 years prior to enrollment

          -  Relative or absolute contraindications to surgery which in the opinion of the
             investigator make the patient a poor candidate for surgical resection.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to panitumumab or other agents used in study.

          -  Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate,
             cyclosporine).

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any
             evidence of interstitial lung disease on baseline chest CT scan.

          -  History of any medical or psychiatric condition or laboratory abnormality that in the
             opinion of the investigator may increase the risks associated with the study
             participation or investigational product(s) administration or may interfere with the
             interpretation of the results.

          -  Subject unwilling or unable to comply with study requirements.

          -  Women who test positive for serum or urine pregnancy test &lt; 72 hours before
             randomization or are breast feeding.

          -  Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus,
             acute or chronic active hepatitis B infection.

          -  Major surgery with 28 days or minor surgery within 14 days of study enrollment.

          -  Men or women of child-bearing potential (women who are post-menopausal &lt; 52 weeks, not
             surgically sterilized, or not abstinent) not consenting to use adequate contraception
             (per institutional standard of care) during the course of the study and after the last
             investigational product(s) administration (24 weeks for women, 4 weeks for men).

          -  Subjects with &gt; grade 1 neuropathy at baseline.

          -  Contraindication to port-a-cath placement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Ryan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David Patrick Ryan, MD</investigator_full_name>
    <investigator_title>Clinical Director, MGH Cancer Center</investigator_title>
  </responsible_party>
  <keyword>gastric</keyword>
  <keyword>esophageal</keyword>
  <keyword>panitumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between June 2008 and July 2010, 17 patients with adenocarcinoma of the stomach were accrued to the protocol at the MGH and Dana Farber Cancer Institute.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
          <description>Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completion of Pre-operative EOX-P</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completion of Surgery/Re-staging</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>17 patients with adenocarcinoma of the stomach were enrolled on this study of perioperative EOX-P.</population>
      <group_list>
        <group group_id="B1">
          <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
          <description>Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="40" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>Safety and tolerability were measured by assessing the number of participants able to complete 3 cycles of pre-operative chemotherapy</description>
        <time_frame>after 3 cycles of pre-operative chemotherapy (approx 21 days per cycle)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
            <description>Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Safety and tolerability were measured by assessing the number of participants able to complete 3 cycles of pre-operative chemotherapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>R0 Resection Rate</title>
        <description>percentage of participants who have microscopically negative margins (no tumor at/near the edge of what is resected) at the time of surgical resection</description>
        <time_frame>time of surgery = after 3 cycles (approx 63 days) of pre-operative EOX-P chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
            <description>Panitumumab in Combination with Epirubicin, Oxaliplatin, and Capecitabine (EOX-P) Chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>R0 Resection Rate</title>
          <description>percentage of participants who have microscopically negative margins (no tumor at/near the edge of what is resected) at the time of surgical resection</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>measured from the first day of treatment to the day when conclusive evidence of new disease is found</description>
        <time_frame>up to 72 months</time_frame>
        <population>We enrolled 17 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
            <description>Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>measured from the first day of treatment to the day when conclusive evidence of new disease is found</description>
          <population>We enrolled 17 patients</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>For patients who undergo complete resection, those who have no evidence of residual viable tumor in the surgical specimen will be declared to have achieved a complete pathologic response (pCR), and the overall percentage of patients with pCR will be determined.</description>
        <time_frame>at surgical resection, after 3 cycles pre-operative chemotherapy (approx 63 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
            <description>Panitumumab in Combination with Epirubicin, Oxaliplatin, and Capecitabine (EOX-P) Chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate</title>
          <description>For patients who undergo complete resection, those who have no evidence of residual viable tumor in the surgical specimen will be declared to have achieved a complete pathologic response (pCR), and the overall percentage of patients with pCR will be determined.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) is the duration from start of treatment to time of death from any cause.</description>
        <time_frame>duration from enrollment to death (up to 6 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
            <description>Panitumumab in Combination with Epirubicin, Oxaliplatin, and Capecitabine (EOX-P) Chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) is the duration from start of treatment to time of death from any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">At time study was closed, this regimen was not to be used in this patient population and therefore overall survival was not followed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug (day 1) throughout time enrolled on study. (June 2008 - January 2011)</time_frame>
      <desc>Adverse events seen in this study were not significantly different from those reported by Waddell T, et. al in Lancet Oncol. 2013 May;14(6):481-9. (NCT00824785). Therefore, only grade 3 and 4 adverse events have been reported here.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epirubicin, Oxaliplatin, Capecitabine, Panitumumab Treatment</title>
          <description>Panitumumab in Combination with Epirubicin, Oxaliplatin and Capecitabine (EOX-P)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin - low</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Leukocytes - low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Platelets - low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen - pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea without prior colostomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fistula - esophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Leak - incl. anastomotic - esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infection - lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated SGPT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Elevated SGOT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was stopped early due to poor tolerability. We will not further study this regimen in this patient population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David P. Ryan</name_or_title>
      <organization>MassGH</organization>
      <phone>617-724-0245</phone>
      <email>dpryan@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

